at MarketWatch.com (Jul 13, 2011)
RTI Biologics (RTIX -13.5%) trades down into the close despite beating Q4 estimates. Profit actually declined 5.5% Y/Y due to inventory issues, which masked a 20% jump in international sales. The company warns on FY12 guidance however, now saying it expects revenue in the range of $174M - $176M. Analysts are looking for sales of $176M.